Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis

Mathurin Fumery, Marion Tilmant, Clara Yzet, Franck Brazier, Julien Loreau, Justine Turpin, Jean Philippe Le Mouel, Vincent Goeb, Eric Nguyen-Khac, Siddarth Singh, et al.

► To cite this version:

Mathurin Fumery, Marion Tilmant, Clara Yzet, Franck Brazier, Julien Loreau, et al.. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Digestive and Liver Disease, 2019, 51, pp.484 - 488. 10.1016/j.dld.2018.12.002 . hal-03486316

HAL Id: hal-03486316

<https://hal.science/hal-03486316>

Submitted on 20 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International License

Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: a systematic review and meta-analysis

Mathurin Fumery^{1,*}, Marion Tilmant^{1,*}, Clara Yzet¹, Franck Brazier¹, Julien Loreau¹, Justine Turpin¹, Jean Philippe Le Mouel¹, Vincent Goeb², Eric Nguyen-Khac¹, Siddarth Singh³, Jean-Louis Dupas¹, Moumar Diouf⁴

¹ Gastroenterology, Amiens University Hospital, Université de Picardie Jules Verne, Amiens, France;

² Rheumatology, Amiens University Hospital, Université de Picardie Jules Verne, Amiens, France;

³ Division of Gastroenterology, Department of Medicine, UC San Diego Health System; La Jolla, USA

⁴ Department of Biostatistics, Amiens University Hospital, Amiens , France.

* Contributed equally

Short Title: premedication for infliximab infusion reaction

Corresponding author:

Mathurin Fumery, MD, PhD
Service Hépato-Gastroentérologie, CHU Amiens Picardie
Université de Picardie Jules Verne
Site Sud - D408, 80054 Amiens, France
Phone: +33 3 22 08 88 40
E-mail: Fumery.mathurin@chu-amiens.fr

Word count: Abstract 286; Manuscript - 3138

References: 25

Tables and Figures: 1 and 3

Disclosures: MF, lecture fees or consultant fees from MSD, Abbvie, Takeda, Ferring, Hospira and Boehringer. JL, lecture fees from Abbvie. SS, Research grants from Pfizer and AbbVie, Consulting fees from AbbVie, Takeda, Pfizer, AMAG Pharmaceuticals

Funding: none

Author Contribution:

Study concept and design: MF
Acquisition of data: MF, MT

Analysis and interpretation of data: MF, MT, MD

Drafting of the manuscript: MF

Critical revision of the manuscript for important intellectual content: MF, MT, MD, CY, FB, JT, VG, SS, JLD

Approval of the final manuscript: MF, MT, MD, CY, FB, JT, VG, SS, JLD

Guarantor of the article: MF

Abstract

Introduction: Up to 25% of patients treated with infliximab experience hypersensitivity reactions. Prophylactic premedication prior to infliximab infusion, comprising corticosteroids and/or antihistamines, is widely used in clinical practice but its efficacy has recently been called into question due to the lack of pathophysiological rationale and validation by controlled trials.

Materials and methods: We conducted a comprehensive literature search of multiple electronic databases from inception to June 2017 to identify studies reporting the impact of corticosteroid and/or antihistamine premedication on the risk of acute (< 24h) hypersensitivity reaction to infliximab in immune-mediated inflammatory diseases (IMIDs). Random-effects meta-analysis was performed.

Results: Ten studies, eight observational studies and two randomized control trials, were identified including a total of 3,892 patients with IMIDs, and 1,385 patients with IBD. Corticosteroid premedication was not associated with a decreased risk of hypersensitivity reaction in either IMIDs (7 studies; OR, 1.07, 95%CI, 0.64-1.78; $I^2 = 57.5\%$) or IBD (3 studies; OR, 1.04, 95%CI, 0.52 - 2.07; $I^2 = 57\%$). Antihistamine premedication was not associated with a decreased risk of hypersensitivity reaction in IMIDs (3 studies: OR, 1.39, 95%CI, 0.70 - 2.73; $I^2 = 85\%$). The combination of corticosteroids and antihistamines did not decrease the risk of acute infliximab infusion reaction in IMIDs (6 studies; OR, 2.12, 95%CI, 0.61 - 7.35; $I^2 = 94\%$), but was associated with an increased risk in IBD (4 studies, OR, 4.17, 95%CI, 1.61 - 10.78; $I^2 = 77\%$).

Conclusion: Corticosteroid and/or antihistamine premedication is not associated with a decreased risk of acute hypersensitivity reactions to infliximab in patients with IMIDs. We believe that these premedications should no longer be part of standard protocols.

Introduction

Infliximab (IFX), a chimeric monoclonal IgG1 antibody directed against tumor necrosis factor, has revolutionized the treatment of immune mediated-inflammatory diseases (IMIDs), including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis (Pso) and psoriatic arthritis. However, administration of IFX is associated with a well-recognized risk of acute infusion reactions, which are reported to occur in about 1-6% of infusions and 5-27% of patients (1-5). Acute infusion reactions associated with IFX range from mild reactions, including fever and chills, dyspnea, pruritus, or urticaria, to severe reactions including anaphylaxis, convulsions, and hypotension. The pathogenesis of these acute infusion reactions remains unclear, with inconsistent findings concerning their allergic/immune nature (5).

Prophylactic corticosteroid and/or antihistamine premedication is widely used in clinical practice, but its efficacy has recently been called into question because of the lack of a pathophysiological rationale for their prophylactic effect. This premedication has been evaluated in two randomized controlled trials (6,7). However, a substantial proportion of healthcare providers still use these drugs before every IFX infusion. In a recent survey, 70% of gastroenterologists reported using an antihistamine and 50% reported using corticosteroids before each infliximab infusion (8). However, patients with IMIDs receive IFX as a steroid-sparing agent, and, although rare, negative effects of short-term administration of intravenous corticosteroid premedication have been reported (9).

In order to more clearly understand the impact of antihistamine or corticosteroid premedication on the risk of IFX-related acute infusion reactions, we therefore conducted a systematic review of the published data and conducted a meta-analysis.

Methods

This systematic review was conducted according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) standards, and according to a previously published protocol (registered at the International Prospective Register of Systematic Reviews, PROSPERO CRD42018086014).

Study Selection

Studies meeting the following criteria were included: (a) randomized controlled trials, observational cohort or case-control studies in (b) adult patients (c) with a diagnosis of RA, AS, Pso, psoriatic arthritis, Crohn's disease or ulcerative colitis, (d) reporting IFX-related acute infusion reactions; (e) patients treated with corticosteroid and/or antihistamine premedication included matched controls; (f) reporting relative risks (RR), hazard ratios (HR), odds ratios (OR), or standardized incidence rates with 95% confidence intervals (CI) or providing data allowing calculation of these parameters. Inclusion was not otherwise restricted by study size, language, or publication type. In the case of multiple publications based on the same cohort, data from the most recent comprehensive report were included.

Search strategy

We conducted a comprehensive search of multiple electronic databases from inception to June 31, 2017 concerning adult patients, with no language restrictions using the following search terms: ("IBD" OR "IMIDs" OR "AS" OR "RA" OR "RA" OR "Pso") AND ("IFX") AND ("infusion reaction") OR ("premedication" OR "steroids" OR "antihistamines"). The databases included MEDLINE, and EMBASE. Conference abstracts (Digestive Disease Week, United European Gastroenterology Week,

European Crohn and Colitis Organization congress, American College of Rheumatology, European League Against Rheumatism, American Academy of Dermatology and European Academy of Dermatology and Venereology annual meetings) from 2015 to 2017, and the references of the selected articles and review articles on the topic were also manually searched for additional studies, with no language restrictions. Two reviewers (MF and MT) independently assessed the title and abstract of studies identified in the primary search for inclusion, and the full texts of the remaining articles were examined to determine whether or not they met the inclusion criteria. Any discrepancy in article selection was resolved by consensus, and discussion with a third reviewer.

Data extraction and definition

Two authors (MF and MT) independently extracted data on: (a) study characteristics: primary author, study period/year of publication, country of the study population, population source, number of patients and/or number of IFX infusions included, duration of follow-up; (b) population characteristics: type of IMiDs; number of IFX infusions; (c) characteristics of infusion reactions: definition of infusion reaction, number of infusion reactions, number of severe infusion reactions; (d) infusion reaction: HRs, ORs, RRs, rate ratios for each premedication and comparator, together with their 95%CI, were recorded. When only incident outcomes were reported, the numbers of events in the groups compared were extracted. When several adjustment models were reported, the most adjusted estimates were used in the analysis.

Data extraction and quality assessment

Data on study-, patient-, infusion-related characteristics, as well as outcomes of interest from the studies included were extracted in a standardized data collection form (MF, MT). Any discrepancies were addressed by joint review of the original article. The methodological quality of studies was assessed using the National Institute of Clinical Excellence (NICE) quality assessment checklist.

Outcome assessed

The outcome measure was an acute infusion reaction, defined by any adverse event occurring during the infusion or within 24h post-infusion, in patients receiving premedication with (a) corticosteroids, (b) antihistamines or (c) a combination of corticosteroids and antihistamines.

Statistical analysis

Assuming inherent heterogeneity between studies, we used the random-effects model described by DerSimonian and Laird to calculate pooled OR (and 95% confidence intervals [CI]) of infusion reactions (10). We assessed heterogeneity between study-specific estimates using the inconsistency index (I^2), with cut-offs of < 30%, 30%-59%, 60%-75% and > 75% to suggest low, moderate, substantial and considerable heterogeneity, respectively (11). A p value < 0.10 was considered to indicate statistically significant heterogeneity using Cochran's Q test. Small study effects were assessed qualitatively using funnel plot asymmetry and quantitatively using Egger's regression test (12). In order to explain heterogeneity, the association between the magnitude of OR and study characteristics was assessed by meta-regression; a p value < 0.10 was considered to be statistically significant. All

statistical analyses were performed with R-Studio software (Version 1.0.143) and SAS[®] software (version 9.4, SAS Institute Inc., Cary, NC).

Results

Literature search

Nine of the 5,150 studies identified by the search strategy met the inclusion criteria (1,6,7,13-18). One abstract was also identified from conference proceedings (19); a total of 10 studies were therefore included for quantitative analysis. **Supplementary Figure 1** shows the study selection diagram.

Characteristics and quality of the studies included

The characteristics of the studies included are described in **Table 1**. Ten studies, including a total of 3,892 patients with IMIDs and 1,935 patients with IBD, comprising a median of 1,667 (IQR: 642 – 3,892) IFX infusions, were included. The acute infusion reaction rate ranged from 2 to 28%. Five studies were conducted in Europe and five were conducted in North America. Two studies were randomized controlled trials and eight were observational studies, including two multicenter studies and three prospective studies. Three studies included patients presenting various IMIDs, three studies only included patients with IBD and one study only included patients with RA. Seven studies evaluated the impact of corticosteroid premedication, three evaluated the impact of antihistamine premedication and six studies evaluated the impact of combinations of corticosteroids and antihistamines. The quality of the studies included, comprising six high-quality studies and four good-quality studies, is shown in **Supplementary Table 1**.

Value of corticosteroid premedication

Seven studies were included. On meta-analysis, corticosteroid premedication was not associated with a decreased risk of acute infusion reactions in IMIDs (OR, 1.07;

95%CI, 0.64 – 1.78) (**Figure 1**) with moderate heterogeneity ($I^2=57.5\%$). Similar results were obtained when the analysis was confined to the three studies including IBD patients (OR, 1.04; 95%CI, 0.52 – 2.07), $I^2=85\%$) (**Figure 2**). One study evaluated impact of betamethasone premedication in patients with RA and failed to demonstrate any protective effect (14.3% vs 10.3%, $p=0.28$) (7).

Value of antihistamine premedication

Three studies, one including patients with IMIDs and two including patients with IBD, were included. On meta-analysis, antihistamines was not associated with a decreased risk of acute infusion reactions in IMIDs (OR, 1.39; 95%CI, 0.70 – 2.73) (**Figure 3**) with considerable heterogeneity ($I^2=84.9\%$).

Value of combined corticosteroid and antihistamine premedication

Six studies were included; four only including patients with IBD and two including patients IMIDs. On meta-analysis, combined corticosteroid and antihistamine premedication was not associated with a decreased risk of acute infusion reactions in IMIDs (OR, 2.12; 95%CI, 0.61 – 7.35) with considerable heterogeneity ($I^2=94\%$). An increased risk of acute infusion reactions was observed in IBD patients following this form of premedication (OR, 4.17; 95%CI, 1.61 – 10.78), $I^2=77.2\%$).

Using meta-regression, the type of premedication (antihistamines and corticosteroids vs. corticosteroids, OR = 2.56 [0.89;7.31]; $p=0.07$) and the duration of follow-up (OR = 1.08 [0.97; 1.21]; $p=0.16$) explained part of the observed heterogeneity. Funnel plots were generated to assess publication bias. The symmetrical distribution of the studies on the funnel plot suggested that no publication bias was observed for the

analysis of corticosteroid premedication ($p=0.61$) or antihistamine premedication ($p=0.78$). In contrast, publication bias was suspected for corticosteroid and antihistamine premedication ($p=0.0015$).

Discussion

IFX therapy is largely prescribed worldwide for the treatment of IBD, RA, AS, Pso and psoriatic arthritis. Administration of IFX is associated with a well-recognized risk of acute infusion reactions. IFX is a chimeric monoclonal antibody with higher immunogenicity than humanized monoclonal antibodies (20). A strong relationship has been described between blood levels of anti-infliximab antibody, observed in about 20% of patients, and acute infusion reactions (14, 21). Corticosteroid premedication is widely used in clinical practice to decrease the formation of anti-drug antibodies, and antihistamines are used to prevent or reduce allergic reactions (8). However, the benefit of these premedications remains a subject of debate. This meta-analysis of ten studies did not demonstrate any benefit of premedication with corticosteroids or antihistamines alone, or in combination, on the risk of IFX-related acute infusion reactions in patients with IMIDs. Two placebo-controlled trials evaluated premedication with intravenous corticosteroids to prevent the incidence of acute infusion reactions. Farrell, et al. randomized 80 patients with CD to hydrocortisone 200 mg or placebo before their first and subsequent IFX infusions. All patients in this trial received episodic/on-demand IFX therapy, a strategy associated with the development of high levels of immunogenicity and a high rate of acute infusion reactions (6). The rate of infusion reactions was not significantly different between the two groups. The trial by Sany et al. was a 36-week trial, in which 355 patients with RA treated by IFX in induction and maintenance therapy were randomized to receive either placebo or intravenous betamethasone premedication. The incidence of acute infusion reactions was higher in the betamethasone group (5.0% vs 2.5%, respectively, $p = 0.05$) (7).

The role of intravenous hydrocortisone premedication to prevent the formation of anti-IFX antibodies and infusion reactions remains unclear. In the randomized controlled trial by Farrell et al., hydrocortisone premedication significantly reduced anti-infliximab antibody levels, but did not totally eliminate their formation or the development of infusion reactions (7).

This meta-analysis showed an increased rate of acute infusion reactions in patients receiving combined corticosteroid and antihistamine premedication, which could be the result of a selection bias whereby patients at high risk of acute infusion reactions were more likely to receive double premedication.

Another factor consistently reported as being associated with IFX-related acute infusion reactions is drug holiday. The present study did not specifically study the impact of premedication in this particular population. Concomitant immunosuppressive agents are the only consistently reported protective factors for prevention of IFX-related acute infusion reactions. Significantly fewer infusion reactions occurred in patients receiving concomitant immunosuppressive therapy compared to patients not receiving concomitant immunosuppressive therapy for RA or IBD (5,14). Combination therapy has also been shown to improve the efficacy and reduce the immunogenicity of IFX (22-25). Many experts recommend an incremental infusion rate schedule to prevent immediate infusion reactions. This strategy is based on the cytokine release mechanism underlying most of these reactions. Although it has never been validated, this strategy would appear to be a reasonable approach for both primary and secondary prevention (6).

This study presents several limitations. Firstly, differences in the definition of acute infusion reaction were observed between studies. Secondly, some of the studies

included patients with a history of acute infusion reaction (secondary prevention). Thirdly, significant heterogeneity was observed across analyses. To evaluate the possible impact of these important limitations, we performed meta-regression to identify prespecified sources of heterogeneity and used a pre-determined definition of acute infusion reaction.

In conclusion, this meta-analysis did not demonstrate any benefit of premedication by corticosteroids, antihistamines or combination of the two on the risk of IF-related acute infusion reaction. These premedications increase the total time spent in the infusion unit and the overall cost of injection. They are also time-consuming for these often young patients, at work or at school. Moreover, some premedications, such as corticosteroids, could have side effects despite low exposure. We believe that these premedications prior to IFX infusion should no longer be part of standard protocols.

References

1. Choquette D, Faraawi R, Chow A, et al. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry. *J Rheumatol*. 2015;42:1105-11
2. Wasserman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. *J Rheumatol*. 2004;31:1912-7.
3. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. *Am J Gastroenterol*. 2003;98:1315-24.
4. Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. *J Rheumatol*. 2012;39:1539-45.
5. Lichtenstein L, Ron Y, Kivity S et al. Infliximab-Related Infusion Reactions: Systematic Review. *J Crohns Colitis*. 2015;9:806-15.
6. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology*. 2003;124:917-24.
7. Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. *Ann Rheum Dis*. 2005;64:1647-9.
8. Picoraro J, Winberry G, Siegel CA, et al. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. *Inflamm Bowel Dis*. 2017;23:174-180.
9. Alexiou C, Kau RJ, Luppia P, Arnold W. Allergic reactions after systemic administration of glucocorticosteroid therapy. *Arch Otolaryngol Head Neck Surg*. 1998;124:1260-4.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
11. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. *J Clin Epidemiol* 2011;64:1294–1302.
12. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. *BMJ* 1997;315:1533–1537.
13. Bartoli F, Bruni C, Cometi L et al. Premedication prevents infusion reactions and improves retention rate during infliximab treatment. *Clin Rheumatol*. 2016;35:2841-2845.

14. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. *Clin Gastroenterol Hepatol*. 2014;12:1474-81.e2.
15. Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. *Aliment Pharmacol Ther*. 2011;34:181-7.
16. Van Assche G, Vermeire S, Noman M, et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. *J Crohns Colitis*. 2010;4:329-33.
17. Keshavarzian A, Mayer L, Salzberg B, et al. A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. *Gastroenterol Hepatol (N Y)*. 2007;3:381-90.
18. Duron C, Goutte M, Pereira B, et al. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. *Eur J Gastroenterol Hepatol*. 2015;27:705-11.
19. Gold SL, Cohen-Mekelburg SA, Schneider Y, et al. Predictors of Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease *Gastroenterology*.2017;152:S584–S585
20. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. *BioDrugs*. 2015;29:241-58.
21. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis*. 2014;20:1-6.
22. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2013;11:444-7.
23. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut*. 2007;56:1226-31.
24. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. *Ann Rheum Dis*. 2013;72:1947-55.
25. Thorne C, Boire G, Chow A, et al. Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study. *Open Rheumatol J*. 2017;11:123-135.

Figures

Figure 1. Impact of corticosteroid premedication on infliximab acute infusion reaction in immune-mediated inflammatory diseases. *AIR: acute infusion reaction; OR, Odds Ratio; CI, confidence interval.*

Figure 2. Impact of corticosteroid premedication on infliximab acute infusion reaction in inflammatory bowel disease. *AIR: acute infusion reaction; OR, Odds Ratio; CI, confidence interval.*

Figure 3. Impact of antihistamine premedication on infliximab acute infusion reaction in immune-mediated inflammatory diseases. *AIR: acute infusion reaction; OR, Odds Ratio; CI, confidence interval.*

Supplementary figure 1. Flow chart. Abbreviations: OR, odds ratio; IR, infusion reaction

Tables

Study	Country	Study period	Number of patients (n)	Number of infusion (n)	Type of IMIDs	Patients with reaction	Infusion with reaction
Bartoli F, 2016	Florence, Italy	2002-2014	105	/	RA, AS, PA	30	30
Choquette D, 2015	Canada	2005-2012	1632	24 852	IBD, RA, AS, PA, Pso	201	322
Baert F, 2014	Leuven, Belgium	/	128	/	IBD	25	/
Lee TW, 2011	Edmonton, Canada	2009	415	2165	IBD, RA, AS, Pso	/	40
Van Assche G, 2010	Belgium, Leuven	2008	177	177	IBD	4	4
Keshavarzian A, 2007	USA	2005	447	6469	IBD	90	226
Farrell RJ, 2003	Boston, USA	2000-2001	80	159	IBD	16	/
Sany J, 2005	France	2001-2002	355	1667	RA	48	63
Duron C, 2015	Clermont, France	2008-2013	80	1107	IBD	23	38
Gold S, 2017	NYC, USA	2008-2016	473	5620	IBD	/	94

Table 1. Study characteristics. Abbreviations: RA, rheumatoid arthritis; AS, ankylosing spondylitis; Pso, psoriasis; RP, Psoriatic arthritis

Author (reference)	Bartoli F, 2016	Choquette D, 2015	Baert F, 2014	Lee TW, 2011	Van Assche G, 2010	Keshavarzian A, 2007	Farrell RJ, 2003	Sany J, 2005	Duron C, 2015	Gold S, 2017
NICE 1: Case series collected in more than one center?	N	Y	N	N	N	Y	N	Y	N	Y
NICE 2: Is the objective of the study clearly described?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
NICE 3: Are the inclusion and exclusion criteria clearly reported?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
NICE 4: Is there a clear definition of the outcome reported?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
NICE 5: Were data collected prospectively?	N	Y	N	Y	Y	N	Y	Y	N	N
NICE 6: Is there an explicit statement that the patients were recruited consecutively?	N	N	Y	Y	Y	Y	N	N	Y	N
NICE 7: Are the main findings of the study clearly described?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
NICE: 8: Are outcomes stratified?	N	Y	N	N	N	N	Y	Y	N	N
Total NICE score	4	7	5	6	6	6	6	7	5	5

[Abbreviations: N-No, NICE- National Institute of Clinical Excellence, Y-Yes]

* A 'yes' in a NICE category is awarded a single point, which is subsequently summed across eight categories to yield a total NICE score

Supplementary Table 1. Quality assessment of case series using the National Institute of Clinical Excellence (NICE) checklist.

Studies	Control group	Corticoïde group	OR	95% CI
	AIR frequency	AIR frequency		

Bartoli F	23/51	7/35	1.01	0.37-2.73
Choquette D	148/12996	14/1243	1.01	0.58-1.76
Baert F	5/33	20/95	2.07	0.71-6.06
Lee TW	5/110	13/177	1.83	0.63-5.27
Farrell RJ	10/41	6/39	0.99	0.32-3.04
Sany J	21/827	42/840	2.13	1.25-3.62
Gold S	17/1249	2/99	1.54	0.35-6.74

Summary

1.07 0.64 - 1.78

Q(df=6)=13.8
p=0.0323
I²=57.5%

Studies	Control group AIR frequency	Corticoïde group AIR frequency	OR	95% CI
---------	--------------------------------	-----------------------------------	----	--------

Baert F	5/33	20/95	2.07	0.71-6.1
Farrell RJ	10/41	6/39	0.99	0.32-3.0
Gold S	17/1249	2/99	1.54	0.35-6.7

Summary

1.04 0.52 - 2.07

Q(df=2)=1.81
p=0.4050
I²=1.2%